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Abstract  
Oral squamous cell carcinoma (OSCC) predominantly affects males in the fifth 
decade of life; nevertheless, an increased incidence in young patients has been reported 
worldwide and the clinical and behavioral characteristics of tumors in this group are 
controversial and the literature shows divergent results. Purpose: To investigate the 
clinicopathological features and prognostic significance of the immunoexpression of 
cell cycle and local invasion proteins in OSCC affecting young patients ( 40 years 
old).  Methods: A tissue microarray was performed with 132 OSCC samples (61 cases 
of young patients vs. 71 cases of elderly patients) and submitted to 
immunohistochemical reactions with Ki67, p53, p16, Bcl-2, Cyclin D1, C-ErbB2, p21, 
Myc, EGFR, MMP-9, SMA, Cathepsin K and FGF-2 antibodies. Results: 
Clinicopathological features and survival rates were similar in both groups. Although 
overexpression of EGFR (p = 0.042) and MMP-9 (p = 0.001) was more frequent in 
young patients, only C-ErbB-2 (p = 0.048) and SMA (p = 0.048) expression correlated 
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with lower DFS in this group of patients.  Conclusion: Clinicopathological features and 
survival rates are similar between younger and older patients with OSCC. The different 
patterns of C-ErbB2, EGFR, MMP-9 and SMA expression between the groups merits 
further investigation to understand their role in the early tumor onset in young patients. 
 
Keywords: Oral squamous cell carcinoma; clinicopathologic characteristics; cell cycle 
proteins; local invasion proteins. 
 
Introduction 
Oral cancer is the sixth most prevalent human cancer1, but it is the most common 
malignancy in some Asian countries2 due to local cultural and social habits3. Oral 
squamous cell carcinoma (OSCC) is the most prevalent histological subtype (over 90% 
of cases) and typically affects males in the fifth and sixth decades of life, with a strong 
association with tobacco and alcohol use4. In the past, OSCC affecting patients younger 
than 40 years was uncommon, representing 4% of all patients5; however, recent 
epidemiological studies have demonstrated a higher incidence in this age group of up to 
18.7%6,7,8,.   
The clinical and behavioral characteristics of tumors in this group are 
controversial and the literature shows divergent results; in spite of a number of reviews 
suggesting the characteristics of the tumors in young people are the same as those found 
in the elderly9,10, other studies describe important differences between the groups11, 12. 
 A better understanding of the molecular basis of OSCC would contribute to our 
understanding of its biological profile and clinical behavior. Hence, analysis of known 
proteins of the cell cycle and local invasion that reflect the biological properties 
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acquired during the complex development of tumors13, would determine if any 
significant difference exists between neoplasms affecting young and old subjects. 
Therefore, the aim of this study was to evaluate and compare the clinicopathological 
features and prognostic significance of the immunoexpression of a large panel of 
regulatory proteins involved in cell cycle control and local invasion in OSCC affecting 
young and elderly patients. We tested the hypothesis that OSCC from young patients 
presents different patterns of expression for cell cycle control and local invasion-related 
proteins when compared to OSCC of older patients. 
Patients and methods 
Tissue samples: Patients younger than 40 years and a control group older than 
45 years, diagnosed with OSCC, were retrospectively retrieved from the archives of the 
A.C. Camargo Cancer Center (São Paulo - Brazil) over a 43-year period from 1968 to 
2011. In addition, the young patients described by Santos-Silva, et al.14 in 2011 were 
included. The cutoff age of 40 years was used following previously published 
recommendations 7, 9-11, 14. 
The original diagnoses were confirmed by reviewing 5-ȝm-thick, H&E-stained 
slides and clinical data were retrieved from patient medical charts. The clinical stage 
was obtained according to Greene et al.15 and grouped as early (stages I and II) or 
advanced (stages III and IV). Histological differentiation was determined according to 
Barnes et al.4 as well differentiated (grade I), moderately differentiated (grade II) and 
poorly differentiated (grade III) tumors.  
Tissue Microarray (TMA) construction: TMAs were created using the tissue 
microarrayer Beecher Instruments®, model MTA-I. (Silver Springs, MD, USA). Tumor 
at the invasive front region were selected and representative cylindrical cores of 1.0 mm 
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diameter were taken from each tissue block and arranged sequentially into a recipient 
paraffin block in duplicate16. 
Immunohistochemistry: Sections were de-waxed with xylene and then re-
hydrated through an ethanol series. After antigen retrieval endogenous peroxidase 
activity was blocked using 3% hydrogen peroxide. Slides were incubated overnight with 
primary antibodies at 4°C. Antibody clones, dilutions, antigen retrievals, sources and 
positive controls are shown in Table 1. Slides were subsequently exposed to either Post 
Primary Block (NovoLink Max Polymer Leica Biosystems, UK) for 30 minutes at 
37°C, or to avidin-biotin complex and horseradish peroxidase reagents (LSAB Kit, 
DakoCytomation, USA). DAB chromogen (Diaminobenzidine Tetrahydrochloride, 
Sigma, St. Louis, USA) was used to visualize the reaction, counterstained with 
Carazzi´s hematoxylin. Negative controls were obtained by omitting the primary 
specific antibody. 
Immunohistochemical analysis: Slides were scanned, obtaining high-resolution 
images, using the Aperio Scanscope CS® Slide Scanner (Aperio Technologies Inc., 
Vista, CA, USA). All digital images obtained in .svs format were visualized with 
ImageScope software (Aperio Technologies Inc., Vista, CA, USA).  Nuclear markers 
(Ki67, p53, Cyclin D1, p21 and Myc) were analyzed using the Nuclear Staining 
function, and the nuclear staining was classified as 0 (no staining), 1+ (weak staining), 
2+ (moderate staining) and 3+ (strong staining). Based on the percentages of nuclei 
classified as 1+, 2+ and 3+ the percentage of positive stained nuclei was expressed in 
the range 0–100%. The expression of nuclear markers was defined following the 
literature17-19 reporting positive expression when more than 10% of cells displayed 
nuclear staining and negative expression when immunoexpression was present in less 
than 10% of tumor cells.  
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Membrane (C-ErbB2 and Epidermal Growth Factor Receptor — EGFR) and 
cytoplasmic (Bcl-2, Matrix Metalloproteinase 9 — MMP-9, Anti-alpha Smooth Muscle 
Actin — SMA, Cathepsin K and Fibroblast Growth Factor 2 — FGF-2) markers were 
analyzed using the PixelCount V9 algorithm and staining was automatically quantified 
according to previously established input parameters20. For statistical purposes, the 
median value of the final immunostaining results was used to split the cases into two 
groups, below and above the median, representing low and high expression levels 
respectively for each membrane and cytoplasmic marker analyzed21.  
Semiquantitative analysis of SMA was jointly carried out by two observers and 
each case was classified as negative (0) (0 to 5% of stromal positivity) or positive (1) 
(>56% of stromal positivity)22.   
Statistical analysis: Absolute and relative frequencies were established for 
clinicopathological features. Chi-square and Fisher tests were used to compare 
clinicopathological features between groups and the nonparametric Mann-Whitney test 
was used to compare the variables. Survival curves were acquired using the Kaplan-
Meier method and a Log-rank test was carried out to evaluate the prognostic 
significance of the clinicopathological features and protein expression. The software 
SPSS Statistics, version 23.0 was employed for data analyses and a p value < 0.05 was 
considered statistically significant.  
Ethical statement: The current study was performed in accordance with the 
ethical standards of the Human Research Ethics Committee of A.C Camargo Cancer 
Center (1957/14).   
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Results.  
Sociodemographic and clinicopathological features: Sixty-one young patients 
( 40 years old) and 71 elderly patients (> 45 years old) (p = 0.001) diagnosed with 
OSCC had complete clinicopathological information and representative tumor tissue 
samples for immunohistochemical analysis. Their sociodemographic and 
clinicopathological features are shown in Table 2 and their correlation with expression 
of proteins in Supplement 1.  
Survival analysis: Recurrences were detected in 24 young (57.1%) and 31 
elderly patients (43.7%) (p = 0.166) and the disease-free survival (DFS) rate did not 
demonstrate a significant difference between the groups (27.3% in the young patients 
vs. 43.4% 5-year DFS in the control group) (p = 0.104). In the young patients, 
recurrence ranged from 0 to 41 months, with a mean time of 8.41 months, while in the 
control patients the recurrence time ranged from 0 to 163 months, with a mean time of 
17.64 months.  
Young patients with T3/T4 lesions demonstrated a lower DFS rate (19.7% vs. 
53.5% 5-year DFS, p = 0.040).  In the old groups a lower DFS was seen in tumors 
located at sites other than the tongue and floor of the mouth (8.5% vs. 53.5% vs. 58.8% 
5-year DFS, p = 0.038), with T3/T4 lesions (33% vs. 58% 5-year DFS, p = 0.028), with 
poorly differentiated tumors  (0% vs. 37.9% vs. 55.6% 5-year DFS, p = 0.001) and in 
tumors with positive surgical margins  (37.5% vs. 53.5% 5-year DFS, p = 0.002). 
Considering all patients, those with T3/T4 lesions (26.8% vs. 57% 5-year DFS, p = 
0.001) and positive margins demonstrated a lower DFS rate (23.1% vs. 44.5% 5-year 
DFS, p = 0.001). 
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The 5-year overall survival (OS) rate was 46.6% in the young patients group and 
44.5% in the control group (p = 0.681). In the young group, mean survival was 27.45 
months (Range 1–128 months), and in the control group it was 27.84 months (Range 0–
172 months). 
Patients with tumors located at sites other than the tongue and floor of the mouth 
(25.5% vs. 57.2% vs. 49.4% 5-year OS, p = 0.043), with T3/T4 lesions (23.9% vs. 
74.9% 5-year OS, p = 0.001), with positive lymph nodes (40.1% vs. 77.8% 5-year OS, p 
= 0.003), advanced stage tumors (35.6% vs. 75.9% 5-year OS, p = 0.001) and with 
positive margins (0% vs. 52.1% 5-year OS, p = 0.001) demonstrated a lower OS rate. 
Regarding young patients only, those using tobacco (39.8% vs. 66.7% 5-year OS, p = 
0.034), with T3/T4 lesions (24.7% vs. 74.3% 5-year OS, p = 0.001), advanced stage 
tumors (31.9% vs. 77.8% 5-year OS, p = 0.001) and with positive margins demonstrated 
(0% vs. 45.4% 5-year OS, p = 0.001) a lower OS rate. Considering old patients only, 
those affected by tumors located in sites other than the tongue and floor of the mouth 
(30.3% vs. 55.2% vs. 61.7% 5-year OS, p = 0.010), with T3/T4 lesions (22.8% vs. 
75.2% 5-year OS, p = 0.001) and with positive surgical margins (0% vs. 59.1% 5-year 
OS, p = 0.001) demonstrated a lower OS rate.     
Immunohistochemical expression of proteins: The immunohistochemical 
expression data of all evaluated proteins and comparisons between the groups of 
younger and older patients are presented in Figure 1.  There were significant 
differences between young and old patients in the expression of EGFR (p = 0.042) and 
MMP-9 (p = 0.001). 
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EGFR was expressed in the membrane and cytoplasm of neoplastic cells with a 
median positivity of 174.95, with young patients demonstrating a higher expression than 
older patients (61.3% vs. 40.7% respectively) (p = 0.042) (Figure 2). EGFR was 
correlated with patients who reported alcohol consumption (56.3% vs. 17.6%, p= 
0.009), but it did not influence survival in the studied sample (Table 3).  
MMP-9 was expressed in the cytoplasm of neoplastic cells and showed a median 
of 107.97, with young patients showing significantly higher expression than older 
patients (68% vs. 34.5% respectively) (p = 0.001) (Figure 2). Considering all patients, 
higher expression of MMP-9 was associated with anatomical site, tumor size, metastatic 
lymph nodes and clinical stage. In young patients, it was associated with tumors located 
on the tongue, tumor size and advanced clinical stage, whereas in the old subjects it was 
associated only with tumor size. MMP-9 did not correlate with survival rates (Table 3).   
Although there were no significant differences between young and control 
groups in the expression of C-ErbB2, Myc, SMA and FGF-2, their expression was 
correlated with survival. C-ErbB2 and SMA were associated with a lower DFS in the 
young group (8.8% vs. 43.4% 5-years DFS, p = 0.048 and 26% vs. 37.5% 5-year DFS, p 
= 0.018 respectively); Myc influenced the OS (0% vs. 47.6% 5-year OS, p = 0.010 in 
young and 0% vs. 44.9% 5-years OS p = 0.001 in old patients) in both groups of 
patients; and FGF-2 was associated with a lower OS in the young patients (33.3% vs. 
55.9% 5-year OS, p = 0.023) and a decreased in DFS in old patients (22.6% vs. 52% 5-
year DFS, p = 0.032) (Table 3). The other evaluated proteins did not show differences 
between the age groups and did not influence survival. The results are shown in Figure 
1 and Table 3. 
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Discussion 
A higher incidence of OSCC among young people has been recently reported in 
different countries worldwide6-8, nevertheless the clinical and biological behavior of 
these tumors is still a matter of discussion.  Therefore, studies that analyze the 
clinicopathological features and the molecular basis of OSCC affecting this specific 
population are of the utmost importance. 
A major limitation for better understating of OSCC in young patients is a lack of 
consensus regarding the most appropriate cut-off age. The literature uses values ranging 
from 30–50 years5-9, 12, making it difficult to compare results. Nevertheless, previously 
published studies from our research group10,14,22 have demonstrated interesting findings 
using 40 years as a cut-off age. As demonstrated in the present sample, OSCC affects 
mainly male patients, and this has also been true for young patients11, possibly due to 
the higher incidence of tobacco and alcohol use by males4. However, in samples where 
these social habits are not present, young females were shown to be more affected14. 
This was also seen in our sample (data not shown).  
Tobacco and alcohol consumption are considered the main etiological agents 
associated with the development of OSCC2. However, the role of these habits in young 
patients is controversial due to the supposed absence or short time of exposure to these 
factors in younger populations. This assumption should be taken with care, since our 
sample of young patients showed a high prevalence of smoking and drinking; 
suggesting a significant increase in these habits in the young population, in agreement 
with Ribeiro et al.9. On the other hand, oral cancer is a recognizable multifactorial 
disease and other etiological agents might be playing important roles in cases not 
associated with well-known environmental factors. Moreover, our group has previously 
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demonstrated a higher frequency of DNA ploidy abnormalities in young patients14, 
suggesting that increased genomic instability is present in these individuals compared 
with older patients23.  
To determine the distribution of OSCC among young and old patients, we aimed 
to characterize the clinicopathological factors that could influence the survival rates of 
this group. We identified that advanced tumor size (T3/T4) was significantly correlated 
with decreased DFS and OS, while positive surgical margins determined a lower OS 
rate in both groups. These results are in agreement with a previous report24 and 
highlight the importance of early diagnosis and appropriate surgical management of 
tumors in any population. Nevertheless, the presence of lymph node metastases and 
advanced clinical stage tumors (III/IV) determined a worse OS in the young patients 
only, probably because of the presence of comorbidities in old patients that may 
influence OS rates.   
Alterations in several cellular processes allow neoplastic onset and development; 
these processed were described by Hanahan and Weinberg in 2000 and denominated 
hallmarks of cancer25. The first alteration is ‘Self-Sufficiency in Growth Signals’ 
including control of the cell cycle by the alteration of the proteins involved in its 
regulation, such as the receptors of growth factors (EGFR and C-ErbB2). In the present 
study, the expression of EGFR was higher in the young patients than in the elderly ones 
and the over-expression of C-ErbB2 was associated with a lower DFS in young 
individuals, suggesting that in this age group these members of ErbB family may be 
involved in the early development and progression of OSCC tumors. These findings 
have potential implications for the treatment, as Cetuximab (a selective EGFR-inhibitor) 
is a targeted therapy drug approved for the use in OSCC patients. In this scenario, the 
amount of EGF is a predictive biomarker for the response to chemotherapy26 and 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
preclinical trials suggest that the combination EGFR/C-ErbB2 may potentiate the effect 
of Cetuximab and decrease resistance27. To date, there are no published results 
concerning the use of Cetuximab in the treatment of OSCC affecting young patients.  
Another important hallmark of cancer is the ability of the neoplastic cells to 
invade tissue and cause metastases25, where the tumor microenvironment (TME) plays 
an important role in molecular interactions between tumor cells and different stromal 
constituents (immune cells, fibroblasts, myofibroblasts, blood vessels and the 
extracellular matrix)28. Matrix metalloproteinases (MMPs) are proteolytic enzymes that 
degrade and remodel the extracellular matrix and basement membrane. They can 
facilitate the invasion of tumor cells and consequently metastasis to distant organs. In 
particular, MMP-9 is overexpressed in 92% of cases of OSCC29. The present 
investigation found a significantly higher expression of MMP-9 in young patients 
compared with older patients, which might account for the higher rate of recurrences 
found in young patients. Also, MMP-9 was correlated with anatomical site, tumor size 
and clinical stage in young patients, while in older subjects it was only associated with 
tumor size, suggesting that MMPs may be highly relevant to the development and 
dissemination of cancer cells in tumors affecting young patients.  
Myofibroblasts are components of the TME that have been identified in 
carcinomas adjacent to nests of tumor cells, and are thought to facilitate invasion of 
malignant cells by the secretion of numerous factors that promote the growth of 
neoplastic cells, tumor invasion and metastasis. We found no significant differences in 
the expression of SMA between young and old patients affected by OSCC, similar to 
the results of Fonseca et al.22 However, expression was correlated with DFS, similarly 
to FGF-2, which is another component of TME that influenced the survival in the 
current sample, demonstrating possible prognostic potentials.  
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Furthermore, C-ErbB2 and Myc proteins influenced the survival of young 
patients affected by OSCC as published in previous studies, highlighting the 
multifactorial molecular background of tumor recurrence and the importance of future 
research to validate these results and analyze in detail the role of these proteins. The 
above-mentioned differences in tumor cells and components of the TME between young 
and old patients may have important roles in the biological basis of tumor susceptibility 
and might represents potential targeting proteins in young patients with OSCC.  
Conversely, the present investigation did not show significant differences in the 
immunohistochemical expression of Ki67, p53, p16, Bcl-2, Cyclin D1, p21 and 
Cathepsin K between young and old patients with OSCC, illustrating the high 
heterogeneity of this disease and the different ways that tumorigenesis may occur in this 
context.  
Interesting, Kaminagakura et al.30 described Cyclin D1 overexpression in young 
patients treated in the same institution and over the same time frame. This contrasting 
result can be explained by differences in the methodology used to analyze the 
immunohistochemistry reactions (their cutoff point for overexpression was 50%) and 
the inclusion of patients from other institutions in our study.  
We demonstrated that young patients with OSCC might have similar survival 
rates to older patients, confirming that OSCC behavior may not be influenced by the age 
of the affected patients. However, we have described differences in C-ErbB2, EGFR, 
MMP-9 and SMA expression between these groups of patients, which might be 
associated with the unusual early development of oral cancer in young patients. These 
results demand additional investigation in order to better characterize these molecular 
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differences and future applicability in the treatment of OSCC affecting young 
individuals. 
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Figure 1. Differences in the immunohistochemical expression of proteins between age 
groups. (A) Nuclear markers. (B) Membrane and cytoplasmic markers. 
 
Figure 2. Comparison of the immunohistochemical expression of EGFR in the 
membrane and cytoplasm of neoplastic epithelial cells, showing strong positivity in 
young patients (A) and moderate positivity in old subjects (B). MMP-9 
immunopositivity was observed in the cytoplasm of tumor cells with a moderate 
reactivity in young patients (C) and weak reactivity in control patients (D).  
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Table 1. Antibodies used for the immunohistochemical analysis 
 
Antibody Clone Dilution 
 
Antigen 
retrieval 
Source 
 
Positive control 
Ki67 MIB-1 1:300 Citric acid  Dako Tonsil 
p53 DO-7 1:300 Citric acid Dako Carcinoma 
p16 E6H4 Ready CC1  Ventana* Cervical carcinoma 
Bcl-2 124 1:50 Citric acid Dako Tonsil 
Cyclin D1 RBT14 Ready EDTA/Tris Biosb Tonsil 
C-ErbB2  1:1500 Citric acid Dako Breast Carcinoma 
p21 SX118 1:50 EDTA/Tris Dako Breast Carcinoma 
Myc 9E.10.3 1:50 EDTA/Tris Thermo Burkitt lymphoma 
EGFR EGFR.25 1:50 Citric acid Leica Placenta 
MMP-9 1:200 Citric acid Thermo Placenta 
SMA 1A4 1:400 Citric acid Dako Endometrium 
Cathepsin K 3F9 1:500 Citric acid Biovendor OSCC 
FGF-2  1:500 Citric acid Chemicon Colon tumor 
*Automated immunohistochemistry 
 
Table 2. Sociodemographic and clinicopathological features 
Feature Young Older p value 
 n (%)  
Age 
  Mean 
  Median 
  Range 
 
34.1 
36 
16-40 
 
61.2 
59 
47-80 
 
0 .001* 
Sex 
  Male 
  Female 
 
45 (73.8) 
16 (26.2) 
 
56 (78.9) 
15 (21.1) 
 
0.490 
Tobacco consumption 
  Yes 
  No 
  NA 
 
44 (72.1) 
14 (23.0) 
3 (4.9)
 
56 (78.9) 
8 (11.3) 
7 (9.9)
 
0.139 
Alcohol consumption 
  Yes 
  No 
 
37 (60.7) 
21 (34.4) 
 
42 (59.2) 
22 (31.0) 
 
0.552 
  NA 3 (4.9) 7 (9.9)  
Anatomical site 
  Tongue 
  Floor of the mouth 
  Other 
 
33 (54.1) 
16 (26.2) 
12 (19.7) 
 
35 (49.3) 
16 (22.5) 
20 (28.2) 
 
0.520 
T classification 
  T1/T2 
  T3/T4 
 
26 (42.6) 
35 (57.4) 
 
30 (42.3) 
41 (57.7) 
 
0.966 
 
N classification 
  N0                                   
  N1-N3 
 
28 (45.9) 
33 (54.1) 
 
25 (35.2) 
46 (64.8) 
 
0.284 
Clinical stage 
  I/II 
  III/IV 
 
16 (26.2) 
45 (73.8) 
 
14 (19.7) 
57 (80.3) 
 
0.495 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
Histological 
differentiation 
  I 
  II 
  III 
 
 
35 (57.5) 
18 (29.5) 
6 (9.8)
 
 
36 (50.8) 
26 (36.6) 
4 (5.6)
 
 
0.477 
  NA 2 (3.2) 5 (7)  
Surgical margins 
  Negative 
  Positive 
 
39 (63.9) 
7 (11.5)
 
42 (59.2) 
4 (5.6)
 
0.261 
  NA 15 (24.6) 25 (35.2)  
Treatment 
  Surgery 
  Radiotherapy 
  Surgery + radiotherapy 
  Surgery + radiotherapy  
+ chemotherapy 
 
18 (29.5) 
1 (1.6) 
29 (47.5) 
2 (3.3) 
 
23 (32.4) 
10 (14.1) 
30 (42.3) 
8 (11.2) 
 
ND 
  NA 11 (18.1) 0 (0)  
Recurrence 
  Yes 
  No 
 
24 (39.4) 
18 (29.5) 
 
31 (43.7) 
40 (56.3) 
 
0.166 
  NA 19 (31.1)  0 (0)
Abbreviations: NA, not available; ND, not determined. *Statistically significant 
difference. 
 
 
Table 3. Correlation between expression of proteins and 5-year survival. 
 Young Control All 
 
Protein 
 
Categ
ory 
OS  
(%
) 
p 
valu
e 
DF
S 
(%
) 
p 
valu
e 
OS 
(%
) 
p 
valu
e 
DF
S 
(%
) 
p 
valu
e 
OS 
(%
) 
p 
valu
e 
DF
S 
(%
) 
p 
val
ue 
Ki67 Low 
High 
25 
45.
6 
0.33
2 
33.
3 
23.
8 
0.90
0 
41.
7 
41.
2 
0.96
9 
41.
5 
39 
0.90
2 
36.
9 
43.
1 
0.71
4 
35.
3 
33.
3 
0.8
45 
p53 Low 
High 
38.
8 
52.
4 
0.39
5 
24.
8 
30.
4 
0.23
5 
42 
42.
4 
0.54
3 
44 
39.
3 
0.87
5 
40.
1 
46.
3 
0.93
3 
35.
8 
36.
1 
0.6
72 
p16 Low 
High 
37.
5 
62.
5
0.28
0 
24.
7 
0 
0.92
7 
39.
7 
44.
4
0.78
8 
33.
2 
52.
7
0.86
2 
38.
5 
49.
7
0.63
3 
30 
44.
7 
0.9
45 
Bcl2 Low 
High 
34.
2 
47.
8
0.59
7 
33.
8 
30.
3 
0.68
4 
39.
3 
40.
7
0.75
1 
38.
5 
35.
5
0.76
6 
37.
1 
44.
3
0.84
6 
36.
6 
33.
7 
0.8
75 
Cyclin 
D1 
Low 
High 
42.
9 
48.
5 
0.87
1 
33.
8 
20.
7 
0.99
0 
49.
7 
35.
9 
0.30
7 
55 
29.
1 
0.33
0 
45.
7 
41 
0.50
3 
43.
2 
26.
6 
0.4
89 
C- Low 26. 0.19 8.8 0.04 36. 0.70 30. 0.34 32. 0.28 23. 0.0
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ErbB2 High 9 
60.
2 
2 43.
4 
8* 5 
53.
2 
7 6 
51.
5 
5 7 
56.
7 
1 3 
48.
7 
58 
p21 Low 
High 
32 
51.
2 
0.34
3 
20.
8 
32.
3 
0.50
8 
47.
1 
37.
9 
0.16
6 
54.
5 
33.
5 
0.25
3 
39.
2 
42.
7 
0.77
6 
34.
3 
33.
1 
0.7
44 
Myc Low 
High 
0 
47.
6 
0.01
0* 
- 
25 
0.37
2 
0 
44.
9 
0.00
1* 
- 
43.
4 
0.81
2 
0 
46 
0.00
1* 
0 
36.
6 
0.4
25 
EGFR Low 
High 
44.
9 
46.
8
0.87
3 
41.
7 
0 
0.22
5 
39.
7 
50.
9
0.64
0 
32.
3 
59.
6
0.23
8 
42.
1 
48.
6
0.87
7 
35.
3 
37.
5 
0.8
60 
MMP-
9 
Low 
High 
40 
48.
3 
0.76
4 
32.
9 
26.
4 
0.93
9 
33.
7 
61.
8 
0.65
5 
39.
2 
55.
3 
0.88
6 
34.
8 
53.
3 
0.59
8 
37.
1 
37.
2 
0.6
96 
SMA Low 
High 
63.
6 
42.
5 
0.25
1 
37.
5 
26 
0.01
8* 
66.
7 
44 
0.14
7 
75 
38.
3 
0.29
1 
64.
7 
43.
3 
0.13
8 
55.
6 
33.
7 
0.4
41 
Cathep
sin K  
Low 
High 
48.
1 
47.
6
0.85
4 
32.
4 
31.
3 
0.73
3 
33.
4 
53.
2
0.43
1 
42.
9 
33.
7
0.32
4 
38.
7 
50 
0.45
9 
38.
5 
33.
9 
0.3
76 
FGF-2 Low 
High 
55.
9 
33.
3 
0.02
3* 
46.
2 
14.
3 
0.16
1 
36.
1 
49.
1 
0.36
7 
22.
6 
52 
0.03
2* 
41 
42.
6 
0.38
6 
31.
7 
38.
6 
0.3
76 
Abbreviations: DFS, disease-free survival; OS overall survival. 
*Statistically significant difference. 
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